XML 68 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue - Incyte Corporation (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended 24 Months Ended
Oct. 31, 2017
Mar. 31, 2019
Jul. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Jan. 31, 2022
Collaboration and Other Agreements [Line Items]                
Revenues       $ 151,941 $ 77,447 $ 104,883    
Incyte Corporation (Incyte) | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                
Collaboration and Other Agreements [Line Items]                
Collaborative arrangement, term               3 years
Collaborative arrangement, extension term               1 year
Incyte MGA012 Agreement | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Non-refundable upfront payment   $ 150,000            
Amounts recognized       100,000        
Transaction price $ 154,000              
Clinical trial activities selling price amount             $ 4,000  
Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Potential proceeds from royalties percent 15.00%              
Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Potential development and regulatory milestone payments $ 435,000              
Potential commercial milestone payments $ 330,000              
Potential proceeds from royalties percent 24.00%              
Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Revenues $ 150,000     30,000 15,000 40,000    
Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Revenues       300 7,800 1,400    
Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Revenues       700 $ 1,500 $ 8,600    
RevenuesFromCMOAgreementsMember | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Non-refundable upfront payment     $ 10,000          
Revenues       8,700        
Deferred revenue       9,600        
Deferred revenue, current       8,100        
Total Annual Fixed Payments       14,400        
Deferred revenue, noncurrent       1,500        
RevenuesFromCMOAmendmentAgreement | Incyte Corporation (Incyte)                
Collaboration and Other Agreements [Line Items]                
Total Annual Fixed Payments       19,500        
Additional Annual Fixed Payments       $ 5,100